MCL1 and leukemia: Next, we assessed whether co-targeting of MCL-1 and BCL-2 would re-sensitize VEN-insensitive leukemia cells and investigated cell death induction by titrating concentrations of VEN, S63845, or their combination (Fig. 2C).